Paola Caruso, Maria Ida Maiorino, Miriam Longo, Chiara Porcellini, Rita Matrone, Lucia Digitale Selvaggio, Maurizio Gicchino, Carla Carbone, Lorenzo Scappaticcio, Giuseppe Bellastella, Dario Giugliano, Katherine Esposito
IMPORTANCE: Peripheral artery disease (PAD) in diabetes may lead to diabetic foot ulcer and lower-extremities amputation. Glucagon-like peptide 1 receptor agonists have proven cardiovascular benefits in trials of people with type 2 diabetes at high cardiovascular risk. OBJECTIVE: To examine the effect of liraglutide on peripheral perfusion measured as peripheral transcutaneous oxygen pressure (TcPo2) in individuals with type 2 diabetes and PAD. DESIGN, SETTING, AND PARTICIPANTS: This open-label randomized clinical trial was conducted between February 1, 2021, and June 30, 2022, with a final follow-up on December 30, 2022, at University of Campania "Luigi Vanvitelli," Naples, Italy...
March 4, 2024: JAMA Network Open